Strengths and Weaknesses of FDA-Approved/Cleared Diagnostic Devices for the Molecular Detection of Respiratory Pathogens

Christine C. Ginocchio
Division of Infectious Disease Diagnostics, Department of Pathology and Laboratory Medicine and Department of Molecular Medicine, North Shore-LIJ Health System Laboratories, Hofstra North Shore-LIJ School of Medicine, Lake Success, New York

The rapid, sensitive, and specific identification of the microbial etiological characteristics of respiratory tract infections enhances the appropriate use of both antibiotics and antiviral agents and reduces the risk of nosocomial transmission. This article reviews the current nucleic acid amplification tests approved by the U.S. Food and Drug Administration (FDA) for the detection of respiratory pathogens. In addition, Emergency Use Authorization tests for the detection of 2009 influenza A H1N1 are discussed. The advantages and limitations of the current FDA-approved/cleared tests are reviewed.

The identification of the causative agent(s) of respiratory tract infections is essential to provide an accurate diagnosis, appropriately manage patient care, and reduce the risk of nosocomial transmission within health care facilities. With the steady rise of antibiotic resistance and limited or no options available for the treatment of multidrug or panresistant bacterial infections, pathogen identification is a key component in restricting antibiotic use to those circumstances in which antibiotic therapy is clearly indicated [1]. Initial empiric therapeutic choices may be standardized and initiated on the basis of patient clinical status, underlying disease, and/or risk for infection with a multidrug-resistant pathogen. However, subsequent bacterial pathogen identification and accurate susceptibility data should assist in promoting switches to targeted specific therapies and reduce the use of broad-spectrum antibiotics when not indicated, thereby promoting good antibiotic stewardship [2].

Nonmolecular Diagnostic Testing for Viral Respiratory Infections

Viral infections probably cause between 75% and 80% of respiratory tract diseases. Nonetheless, it is estimated that 22.6 million (55%) of 41 million antibiotic prescriptions for respiratory tract infections, including both lower and upper respiratory infections, were for causes unlikely to have a bacterial etiology [3]. Although in many cases of otitis and sinusitis and probably 20%–40% of cases of community-acquired pneumonia a bacterial superinfection may occur, respiratory infections due to a virus(es) alone are common in the adult and pediatric outpatient populations. In addition, the vast majority of respiratory tract infections in non-immunocompromised hospitalized children (especially those <5 years of age) are due to 1 or more viruses, without a secondary bacterial infection.

The overuse of antibiotics for the treatment of outpatients is primarily due to the fact that in adults respiratory virus testing is either not performed or generally limited to rapid antigen direct tests (RADTs) for influenza. Testing for the elderly, for persons with chronic obstructive pulmonary disease, and for pediatric patients is limited to RADTs for influenza
and respiratory syncytial virus (RSV). RADTs have highly variable sensitivities (10%–75%) and specificities (50%–100%) depending on the viral target, age of the patient, sample collection, and duration of symptoms prior to testing [4–6]. In general, RADTs perform better when testing pediatric samples, because children shed higher titers of virus and for longer time periods than adults [4, 7–9].

In addition to RADTs, there are U.S. Food and Drug Administration (FDA)-approved/cleared nonmolecular-based viral diagnostic methods with a more rapid time to result, compared with traditional viral tube culture, eg, direct fluorescent antibody (DFA) testing and rapid cell culture. Both methods can readily detect 7 of the common respiratory viruses (adenovirus, influenza A, influenza B, parainfluenza 1, 2, and 3 [PIV-1, PIV-2, PIV-3], and RSV). In addition, DFA testing can detect human metapneumovirus (hMPV) [6]. The specificity of DFA testing and rapid cell culture are high, but the sensitivities of the tests can vary from a low of 50% (RSV culture) to a high of >80% (influenza A), when compared with nucleic acid amplification tests (NAATs) [5, 6, 10]. DFA testing can be performed in as little as 30–60 min, and shell vial and R-Mix rapid cell cultures (Quidel/Diagnostic Hybrids) generally identify respiratory viruses in 24–48 h [6]. If these tests are performed on site, the time to virus detection can be within a time frame that could affect patient management. However, these tests are not widely available outside larger hospitals and reference laboratories. Although these 8 viruses are responsible for a large number of respiratory tract infections, bocavirus, selected coronaviruses (229E, OC43, NL63, and HKU-1), parainfluenza 4, and rhinovirus are also important causes of respiratory disease and are generally only detected using NAATs.

**Clinical and Financial Benefits of Respiratory Virus Diagnostics**

Because antiviral therapies are currently limited to the treatment of influenza A, influenza B, cytomegalovirus pneumonia, and varicella zoster virus pneumonia, it is often argued that the specific identification of other viruses is not relevant, because the information would not change patient management. From a treatment standpoint, this may currently be true; however, the respiratory viruses cause similar illnesses, and diagnosis based on clinical symptoms alone can be highly inaccurate [11]. For example, a study by Poehling et al revealed that physicians who used only clinical symptoms recognized influenza in only 28% of hospitalized children and 17% of nonhospitalized children with laboratory-confirmed influenza [11]. Therefore, establishing the viral etiological characteristics of the illness is often highly dependent on accurate diagnostic testing. In addition, new therapeutic agents for respiratory viruses are in development, and clinical trials for these agents will need rapid diagnostics that detect a broad range of viral pathogens. Once these new drugs are approved, clinical laboratories will need the tools to identify each virus so that appropriate antiviral therapy can be rapidly initiated. In addition, during the first weeks of the 2009 influenza A H1N1 outbreak in the spring of 2009, multiple influenza viruses were cocirculating [5]. It was necessary to subtype influenza A strains to differentiate seasonal influenza A/H1, seasonal influenza A/H3, and 2009 influenza A H1N1. Subtyping is necessary to provide relevant information needed for appropriate selection of antiviral therapy, in particular for acutely ill patients. Antiviral resistance testing of influenza isolates from 2009 (www.cdc.gov/flu) revealed that the circulating seasonal influenza A/H1 strains were resistant to oseltamivir (99.6%), and seasonal influenza A/H3 and 2009 influenza A H1N1 were resistant to the adamantanes (100%). In addition, several patients with 2009 influenza A H1N1 infections developed oseltamivir resistance [12, 13].

Other clinical factors, such as the potential for the development of more severe disease on the basis of the virus etiology, may need to be considered in the management of certain patients. For example, studies from our laboratory have revealed that children with hMPV infections have a higher incidence of admission to an intensive care unit and more often require mechanical ventilation than children with RSV infections [14, 15].

Especially in the treatment of inpatients, the costs of rapid viral diagnostics can be offset by the improvement in patient care and financial outcomes [16–19]. Hendrickson et al showed that rapid respiratory virus diagnosis can lead to benefits in several areas, including up to a 50% reduction in hospital days, 30% reduction in antibiotic use, and 20% reduction in unnecessary diagnostic tests and procedures [16]. The burden of nosocomial influenza can be high, incurring additional costs for diagnostic tests, increased morbidity, and extended hospitalization [17, 18]. Therefore, rapid diagnostic tests are needed to identify patients with influenza at admission, in order to prevent nosocomial transmission by facilitating isolation and cohorting decisions [18]. Studies have documented substantial nosocomial transmission of hMPV in pediatric units [20], as well as in chronic care facilities [21], similar to what is seen with RSV. During the height of RSV season, many institutions must cohort RSV-positive children because of a lack of private rooms. However, dual infections with RSV and hMPV do occur. Limiting diagnostics to RSV alone in a cohorting scenario could put other seriously ill children at risk for acquisition of a second viral infection with hMPV. The meaning of mixed viral infections can be defined only if testing is comprehensive. Broad test panels also allow for monitoring the epidemiologic patterns of respiratory disease and for identifying new or reemerging pathogens. Finally, the identification of the exact respiratory..."
The costs for testing using FDA-approved/cleared NAATs are highly variable and can range from approximately $30 to $200 per test. Factors that determine test cost include test volume, the price of the test kits, the number of tests per kit, size of the testing run, the number of controls required per testing run, and the type and amount of ancillary supplies. Often FDA-approved/cleared kits do not contain nucleic acid extraction reagents, so additional equipment and reagents are necessary and can add $3–$15 per test. Batch testing of samples may reduce the cost per test; however, often batching is not practical if the time to result is delayed beyond a period that would affect either clinical management or infection control practices. Instrumentation costs for molecular tests can be substantial, with real-time instrumentation costing on average $35,000–$85,000 per instrument, and higher volume laboratories may require multiple instruments. Laboratories must also calculate the cost for technical time, which is again highly variable depending on the test complexity and run size. Finally, the costs for quality control, proficiency testing, and competency assessment all affect the overall cost per test. In deciding which tests are appropriate and at what cost for the patient population at a particular health care facility, all of the above factors need to be considered in light of the clinical impact of the test result.

**USE OF NUCLEIC ACID AMPLIFICATION TESTS**

The use of NAATs is an intrinsic part of infectious disease diagnostics. The ability of NAATs to rapidly and accurately detect a novel pathogen was best exemplified during the 2009 influenza A H1N1 pandemic [5, 22–24]. NAATs are especially suited for the identification of respiratory pathogens that are not routinely or easily cultured (eg, hMPV, bocavirus, parainfluenza 4, and *Chlamydophila pneumoniae*), pathogens that are dangerous to culture (eg, severe acute respiratory syndrome coronavirus), pathogens for which the time to detection by traditional means is often too delayed to affect patient care (eg, tube cell culture for influenza), and pathogens for which serologic testing is difficult to interpret (eg, *C. pneumoniae*). In most cases, NAATs offer enhanced sensitivity over culture methods, RADTs, and DFA testing [5, 6, 10]. The specificity of NAATs varies with target and assay design but is generally very high. In addition, laboratory-developed NAATs validated in accordance with the Clinical Laboratory Improvement Amendments (CLIA) requirements can be used to identify new pathogens until FDA-approved/cleared in vitro diagnostic (IVD) devices become available. With clinical integration of real-time polymerase chain reaction (PCR) and FDA-approved/cleared simple cartridge-based NAATs, laboratories of all sizes are now able to perform molecular diagnostic tests.

**FDA-APPROVED/CLEARED TESTS FOR THE MOLECULAR DETECTION OF NONVIRAL RESPIRATORY PATHOGENS**

The detection of *Mycobacterium tuberculosis* directly in a clinical sample from a patient not yet identified as *M. tuberculosis* positive is always clinically relevant. Detection of such bacterial pathogens as *Bordetella pertussis*, *Bordetella parapertussis*, *Legionella pneumophila*, *Mycoplasma pneumoniae*, or *C. pneumoniae* usually indicates active infection. In contrast, the detection of other bacteria, such as *Streptococcus pneumoniae*, may indicate infection or simply colonization. Therefore, interpretation of the molecular detection of many bacterial pathogens must be viewed in light of the clinical specimen (sterile vs nonsterile body site) and determination of the quantity of organisms present. In addition, molecular methods must include all potential pathogens, even though culture is still required for antimicrobial susceptibility testing. For these reasons, there is currently a scarcity of FDA-approved/cleared assays for nonviral respiratory pathogens (Table 1). For such targets as the atypical pneumonia pathogens, the interpretation of NAAT results is generally not an issue, quantitative tests are not necessarily indicated, and NAATS could replace traditional test methods. However, the lack of FDA-approved/cleared NAATs for these pathogens most probably relates to the IVD device manufacturers’ reluctance to perform costly clinical trials for targets with a relatively low prevalence rate and for which the potential volume of testing may be minimal.

**FDA-Approved Assays for the Detection of *M. tuberculosis* Complex**

In light of the rise in *M. tuberculosis* drug resistance worldwide, the rapid identification of patients with pulmonary tuberculosis is essential and allows for improved patient outcomes, the appropriate use of isolation facilities, the initiation of appropriate treatment, and the identification of possible infected contacts [25–27]. In addition, studies have shown that the estimated costs associated with an inaccurate diagnosis of *M. tuberculosis* infection are substantial ($11,576 per patient) because of institutional isolation procedures [27]. Direct sample testing can detect *M. tuberculosis* within 24–48 h of sample collection, compared with 1–4 weeks for liquid and traditional solid media culture methods. Although acid-fast bacilli (AFB) smear microscopy is inexpensive and rapid to perform, the sensitivity of the test can be poor (45%–80% with culture-confirmed pulmonary *M. tuberculosis* colonization or infection) and cannot differentiate *M. tuberculosis* from mycobacteria other than *M. tuberculosis* [26]. The 2009 Centers for Disease Control and Prevention (CDC) guidelines recommend that NAATs should be performed on at least 1 respiratory sample from patients with signs and symptoms of pulmonary *M. tuberculosis* colonization.
Amplified Mycobacterium tuberculosis Test (AmpliCor, Roche Diagnostics)

The AmpliCor Mycobacterium tuberculosis test is FDA approved for use with AFB smear–positive respiratory specimens from patients suspected of having Mycobacterium tuberculosis infection or colonization [32–35]. The AmpliCor Mycobacterium tuberculosis test uses traditional PCR to amplify a region of the gene encoding the 16S rRNA of all mycobacteria. Members of the M. tuberculosis complex are identified after hybridization with a DNA target–specific probe, followed by substrate addition and colorimetric detection [32]. When testing AFB smear–positive samples, the AmpliCor Mycobacterium tuberculosis test demonstrated sensitivities and specificities for the detection of M. tuberculosis complex ranging from 92.9% to 100% and from 77.3% to 100%, respectively [32, 33]. The sensitivities and specificities of AmpliCor Mycobacterium tuberculosis for AFB smear–negative specimens ranged from 51.2% to 73.1% and 99% to 99.8%, respectively [32, 33]. The AmpliCor Mycobacterium tuberculosis test has also been evaluated for detection of M. tuberculosis meningitis [34] and for use with nonrespiratory sample types [35].

FDA-APPROVED/CLEARED TESTS FOR THE DETECTION OF RESPIRATORY VIRUSES

Viral respiratory pathogens are particularly suited for detection using NAAT, since the number of targets is relatively limited, compared with the numerous potential bacterial pathogens that can cause respiratory disease (Table 1). Although there is much to learn regarding the clinical relevance of mixed viral respiratory infections, the detection of a respiratory virus is generally considered diagnostic at this time. Today, most laboratories do not have the facilities for comprehensive tissue culture based viral diagnostics and therefore are limited to testing with less sensitive and less specific RADTs for only influenza A, influenza B, and RSV. NAATS offer an excellent alternative to greatly expand the test menu of clinical laboratories, thereby providing rapid, accurate comprehensive diagnostics.

Luminex xTAG Respiratory Virus Panel (Luminex Molecular Diagnostics)

The first multiplex NAAT to receive clearance by the FDA was the xTAG respiratory virus panel (RVP) assay in January 2008. The FDA-approved version of RVP detects adenovirus, influenza A (with subtyping of seasonal influenza A/H1 and seasonal influenza A/H3), influenza B, PIV-1, PIV-2, PIV-3, hMPV, rhinovirus, RSV A, and RSV B [37, 38]. The US/Canadian research use–only version of the assay also detects 4 coronaviruses (OC43, 229E, NL63, and HKU-1), parainfluenza type 4, and enterovirus. The test is approved for use with nasopharyngeal swab samples collected from persons symptomatic for a respiratory virus infection and placed in viral transport media.
### Table 1. Food and Drug Administration-Approved/Cleared Tests for the Detection of Respiratory Pathogens (as of July 2010)

<table>
<thead>
<tr>
<th>Manufacturer and test name</th>
<th>Year approved&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Test method</th>
<th>Instrument</th>
<th>Specimen type</th>
<th>Gene target</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Gen-Probe Amplified Mycobacterium tuberculosis Direct Test (AMTD)</td>
<td>1995</td>
<td>TMA, HPA</td>
<td>Gen-Probe Leader 50</td>
<td>AFB smear-positive and smear-negative respiratory specimens</td>
<td><em>M. tuberculosis</em> complex rRNA</td>
</tr>
<tr>
<td>2. Gen-Probe/Prodesse ProFlu</td>
<td>2008</td>
<td>Real-Time RT-PCR</td>
<td>Cepheid SmartCycler</td>
<td>Nasopharyngeal swab in VTM</td>
<td>RSV P, influenza A M, influenza B NS1 and NS2</td>
</tr>
<tr>
<td>3. Gen-Probe/Prodesse Pro hMPV</td>
<td>2008</td>
<td>Real-Time RT-PCR</td>
<td>Cepheid SmartCycler</td>
<td>Nasopharyngeal swab in VTM</td>
<td>hMPV NC</td>
</tr>
<tr>
<td>4. Gen-Probe/Prodesse ProParaFlu</td>
<td>2009</td>
<td>Real-Time RT-PCR</td>
<td>Cepheid SmartCycler</td>
<td>Nasopharyngeal swab in VTM</td>
<td>PIV-1, 2, 3 HN</td>
</tr>
<tr>
<td>5. Luminex xTAG Respiratory Virus Panel</td>
<td>2008</td>
<td>RT-PCR, TSPE, bead hybridization</td>
<td>Luminex xMap 100/200</td>
<td>Nasopharyngeal swab in VTM</td>
<td>Influenza A M and HA, influenza B HA, hMPV NP, RSV RP, PIV-1, 2, 3 HA, adenovirus HEX, rhinovirus 5' UTR</td>
</tr>
<tr>
<td>7. Roche Amplicor Mycobacterium tuberculosis Direct Test</td>
<td>1996</td>
<td>PCR, colorimetric detection</td>
<td>Thermocycler EIA reader</td>
<td>AFB smear-positive respiratory specimens</td>
<td><em>M. tuberculosis</em> complex rDNA</td>
</tr>
</tbody>
</table>

---

**NOTE.** AFB, acid-fast bacilli; EIA, enzyme immunoassay; F, fusion gene; HA, hemagglutinin gene; HEX, hexon gene; hMPV, human metapneumovirus; HN, hemagglutinin-neuraminidase genes; HPA, hybridization protection assay; L, L nucleic acid sequence; M, matrix gene; NC, nucleocapsid gene; NP, nucleoprotein gene; NS, nonstructural gene; P, polymerase gene; PIV-1, 2, 3, parainfluenza virus types 1, 2, and 3; rDNA, ribosomal DNA; rRNA, ribosomal RNA; RP, RNA polymerase gene; RVP, respiratory syncytial virus; RT-PCR, reverse transcription polymerase chain reaction; TMA, transcription-mediated amplification; TSPE, target-specific primer extension; UTR, untranslated region; VTM, viral transport medium.

<sup>a</sup> Year of initial FDA approval/clearance.
RVP assay and nasopharyngeal swab specimens, compared xTAG RVP with a combination of DFA testing and viral culture [37]. For viruses that can be grown in culture, the overall sensitivities and specificities of DFA testing/culture were 91.9% and 98.2%, respectively, compared with 97.8% and 96.4%, respectively, for xTAG RVP. When viruses not routinely cultured were also included in the evaluation, the sensitivity of DFA testing/culture was 68.8%, compared with 98.4% for xTAG RVP. In addition, 5.2% of the specimens contained >1 virus. Wong et al found that the highly multiplexed xTAG RVP assay enhanced laboratory investigations of respiratory virus outbreaks and aided health care facilities in both patient and outbreak management [39]. Studies that evaluated the performance of xTAG RVP during the 2009 influenza A H1N1 outbreak in the area of New York, New York, demonstrated that the sensitivity of xTAG RVP for the detection of 2009 influenza A H1N1 was 97.6%, compared with 88.9% for R-Mix culture, 46.7% for DFA testing, and 17.8% for RADTs [5]. xTAG RVP detected a respiratory virus in 60% of the samples, of which 36% were 2009 influenza A H1N1. Numerous mixed viral infections were also identified. Ginocchio and St. George determined that the probability of an influenza A infection due to an unsubtypeable strain (not seasonal influenza A/H1 or seasonal influenza A/H3 according to the xTAG RVP assay), identified during the outbreak, was >99% for identification as 2009 influenza A H1N1 [24]. On the basis of these 2 studies, the FDA approved changes to the package insert that state that xTAG RVP can be an effective aid in the detection of 2009 influenza A H1N1 but cannot specifically identify the 2009 influenza A H1N1 hemagglutinin gene.

The benefits of the xTAG RVP assay include the broad spectrum of viruses detected by a single test, with a cost per test comparable to real-time assays that only target up to 3 analytes. The subtyping of influenza A viruses as seasonal influenza A/H1 or seasonal influenza A/H3 or the identification of an “unsubtypeable” virus has proven to be an important aid in identifying novel influenza A strains. A limitation of the assay is the decreased sensitivity for the detection of certain adenovirus strains. In-house validation studies by our laboratory have found that by reducing the positive cutoff MFI level from 300 to 150 for adenovirus, improved sensitivity for the detection of adenovirus was obtained without loss of specificity (unpublished data). Additional limitations of the assay include the time to final results, number of required steps, technical hands-on time, and a potential for amplicon contamination. There is a second-generation assay called RVP FAST (Luminex) available in Europe that addresses several of these issues by reducing the number of steps and the time to results by 3–4 h, making it possible to provide comprehensive results within a single shift.

**Gen-Probe/Prodesse ProFlu+, ProFlu-ST, Pro hMPV+, and ProParaflu+ Assays (Gen-Probe/Prodesse)**

Currently, there are 3 Gen-Probe/Prodesse FDA-cleared multiplex real-time RT-PCR assays for the qualitative detection and discrimination of respiratory viruses. The ProFlu+ assay targets the matrix gene for influenza A, nonstructural genes NS-1 and

---

**Figure 1.** The xTAG Respiratory Virus Panel (RVP) is a multistep test that takes approximately 8–10 h to complete, depending on the number of samples to be tested. RT-PCR, reverse transcription polymerase chain reaction; TSPE, target-specific primer extension.
NS-2 for influenza B, and the polymerase gene for RSV A and RSV B. The Pro hMPV+ assay targets highly conserved regions of the nucleocapsid (N) gene for hMPV and a transcript derived from Escherichia coli Bacteriophages MS2 A-protein gene (Internal Control). The ProParaflu+ assay targets conserved regions of the hemagglutinin-neuraminidase gene for PIV-1, PIV-2, and PIV-3 and a transcript derived from E. coli Bacteriophage MS2 A-protein gene (Internal Control). All 3 assays are approved for testing nasopharyngeal swab specimens obtained from symptomatic persons.

Viral nucleic acids from patient samples are coextracted with an internal control that monitors assay performance and the presence of amplification inhibitors that could lead to false-negative results. Nucleic acids are extracted using a MagNA Pure LC System and the Automated Magnetic Extraction Reagents (bioMérieux). The purified nucleic acids are amplified by means of RT-PCR using target-specific oligonucleotide primers and Taqman probes complementary to highly conserved regions of the target gene. The Taqman probes are labeled with a quencher dye attached to the 3'-end and a reporter dye at the 5'-end. During each PCR cycle, the fluorescent intensity is monitored by real-time instrument, the SmartCycler II (time to results, including extraction, is approximately 3–3.5 hr for each test run).

The performance characteristics of the assays were established by the manufacturer through prospective and retrospective clinical studies used for FDA clearance of the tests. ProFlu+ assay results obtained by testing 891 nasopharyngeal samples were compared with results of rapid shell vial culture. ProFlu+ sensitivities and specificities for the detection of influenza A were 100% and 92.6%, respectively; for influenza B were 97.8% and 98.6%, respectively; and for RSV were 89.5% and 94.9%, respectively [102]. A study by Liao et al compared the Prodesse and received Emergency Use Authorization (EUA) from the FDA in July 2009 (see EUA section). ProFlu-ST is a qualitative multiplex real-time RT-PCR assay that targets the nucleoprotein gene of 2009 influenza A H1N1, the specific hemagglutinin genes of seasonal influenza A/H1 and seasonal influenza A/H3, and an internal control (MS2 phage). The identification of 2009 influenza A H1N1 is aided by an algorithm that relies on seasonal influenza A/H1 virus and seasonal influenza A/H3 virus results in nasopharyngeal swab specimens from patients who receive a diagnosis of influenza A by a currently available FDA-cleared or authorized device. This assay is intended for use in only CLIA high-complexity laboratories. The performance of the assay was evaluated retrospectively using nasopharyngeal swab specimens that were previously tested with either the CDC rRT-PCR Flu Panel (IVD device) to detect seasonal influenza A/H1 and influenza A/H3 or the CDC rRTPCR Swine Flu Panel (EUA). The positive and negative agreements for the detection of seasonal influenza A/H1 were 95.8% and 100%, respectively; for seasonal influenza A/H3 were 100% and 100%, respectively; and for 2009 influenza A H1N1 were 96.2% and 100%, respectively [103].

The Pro hMPV+ assay clinical trial study for FDA clearance evaluated the assay’s clinical performance using 1275 nasopharyngeal swab specimens tested by 4 clinical laboratories across the United States. Using the Luminex RVP assay as the predicate device, the sensitivity of Pro hMPV+ was 94.1% and the specificity was 99.3% [104].

Figure 2. The Verigene System consists of 2 instruments (the fully automated Verigene Processor and the Verigene Reader) and single-use test cartridges.
The performance of the ProParaflu+ assay was evaluated during the clinical trials for FDA clearance. Using 857 nasopharyngeal swab specimens tested by 4 clinical laboratories across the United States [105], the sensitivities and specificities of the assay for the detection of PIV-1 were 88.9% and 99.9%, respectively; for the detection of PIV-2 were 96.3% and 99.8%, respectively, and for the detection of PIV-3 were 97.3% and 99.2%, respectively [105]. At this time, no additional independent performance data are available.

The benefits of the Gen-Probe/Prodesse assays include ease of use, with approximately 1.5 h of hands-on time for nucleic acid extraction preparation and a 1-step RT-PCR setup. The overall time to results is 4.5–5.5 h. Multiple SmartCycler instruments can be run simultaneously, with as many units per cycler used as needed, giving flexibility to run sizes. Because tubes containing amplicons are never opened, the risk of amplicon contamination is minimal. One limitation of the assays is a maximum of 3 targets plus an internal control that can be detected in a single reaction. Therefore, a comprehensive viral diagnostic panel requires multiple PCRs. Multiple PCRs are costly to the laboratory in both technical time and reagent cost. However, the limited panel size could provide a mix-and-match test menu, allowing clinicians the option of selecting 1 or several panels.

**Nanosphere Verigene Respiratory Virus Nucleic Acid Test (VRNATsp) (Nanosphere)**

The first-generation Verigene Respiratory Virus Nucleic Acid Test (VRNAT) was cleared by the FDA in May 2009. This test has been replaced by the automated Verigene VRNATsp, a CLIA moderately complex test that is intended for the identification of influenza A, influenza B, and RSV (types A and B inclusive) from nasopharyngeal swab specimens placed in viral transport media. The Verigene System consists of 2 instruments (the fully automated Verigene Processor and the Verigene Reader) and single-use test cartridges (Figure 2). The entire test process only requires 1 user pipetting step, less than 5 min of technical hands-on time, and a sample-to-result turnaround time of about 3.5 h.

The basis of VRNATsp is Nanosphere’s proprietary gold nanoparticle hybridization technology [41]. The gold nanoparticles contain a high density (~200) of sequence-specific oligonucleotides with a high affinity for complementary DNA, which allows for very efficient hybridization kinetics. The clinical sample is pipetted into a single-use extraction tray, which is loaded into the Verigene processing unit. Chaotropic agents are added to the sample to lyse cells, viral particles, and an internal control (MS2 phage) that is added prior to the extraction step. The released nucleic acids are then captured on magnetic microparticles (MMPs). The MMP-bound nucleic acids are washed, and the purified nucleic acids are eluted from the MMPs and transferred to the amplification tray. A 1-step RT-PCR is performed using primers that target the influenza A matrix gene, the influenza B matrix gene and nonstructural gene, and the RSV L gene and F gene.

The RT-PCR reaction is followed by the primary hybridization step. During primary hybridization, target DNA is simultaneously hybridized to target-specific capture DNA oligonucleotides arrayed in replicate on a solid substrate (a microarray) and to target-specific mediator DNA oligonucleotides. After removal of unhybridized target nucleic acids and unhybridized mediator oligonucleotides, the process continues with the secondary hybridization. Each microarray spot, where an appropriate target is hybridized to capture both an oligonucleotide and a mediator oligonucleotide, is saturated with silver-coated gold nanoparticle probes. After hybridization, the cartridge is removed from the processor unit and the glass slide (microarray) is separated from the cartridge and inserted into the Verigene Reader. A light-scattering technique, in which the slide is illuminated internally with light parallel to the slide surface, is used to analyze the results. Spots where silver-enhanced gold nanoparticle probes are present scatter this light, and the light scatter is detected optically and translated into a measurable signal.

The performance characteristics of the first-generation VRNAT assay were established during the clinical trials for IVD device clearance. VRNAT was compared with viral culture/DFA testing with bidirectional sequencing to resolve discordant results. Test sensitivities and specificities for the detection of influenza A were 100% and 99.8%, respectively; for influenza B were 100% and 99.1%, respectively; and for RSV were 95.7% and 98.2%, respectively [106]. Comparison of VRNAT with VRNATsp revealed an overall positive agreement of 97.9% and a negative agreement value of 100% [107].

The benefits of the VRNATsp System include the scalability of the system (addition of multiple processors and readers), individual sample processing with random access format, minimal hands-on time, and minimal technical expertise required to perform the test. Because this test is CLIA moderate complexity, trained laboratory technicians could perform the testing. This test would be well suited for small- to medium-sized laboratories, in particular for laboratories with little or no molecular testing experience. Limitations of the assay include the single test format that requires a dedicated processor for each sample for 3–3.5 h. Multiple processor units would be needed for larger volume laboratories, and the additional instrumentation would increase costs for the lab, compared with using an instrument that can run multiple tests at a time.

**FDA Emergency Use Authorization Tests for 2009 Influenza A H1N1 (as of 22 March 2010)**

In response to the emergence of pandemic 2009 influenza A H1N1, on 26 April 2009 the Secretary of the Department of Health and Human Services (DHHS) determined that there was...
<table>
<thead>
<tr>
<th>Manufacturer name and test name</th>
<th>Date</th>
<th>TBT method</th>
<th>Instrument</th>
<th>Specimen types</th>
<th>Gene targets</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. CDC Human Influenza Virus Real time RT-PCR Detection panel</td>
<td>2 May 2009</td>
<td>Real-time RT-PCR</td>
<td>Roche LightCycler 2.0</td>
<td>NPS, NS, TS, NPS/TS</td>
<td>FluA M</td>
</tr>
<tr>
<td></td>
<td>18 Dec 2009</td>
<td>Real-time RT-PCR</td>
<td>ABI 7500 Fast Dx ABI 7500</td>
<td>NA, BAL, BA, BW, EA</td>
<td>swFluA NP</td>
</tr>
<tr>
<td></td>
<td>18 Dec 2009</td>
<td>Real-time RT-PCR</td>
<td>JBAIDS¹</td>
<td>EW, TA, lung tissue</td>
<td>swH1FluA HA</td>
</tr>
<tr>
<td>2. Cepheid Xpert Flu A Panel</td>
<td>24 Dec 2009</td>
<td>Real-time RT-PCR</td>
<td>Cepheid GeneXpert Dx</td>
<td>NA, NW, NPS</td>
<td>FluA M, swH1FluA HA</td>
</tr>
<tr>
<td>3. Diagnostic Hybrids D3 Ultra 2009 H1N1 Influenza A Virus ID Kit</td>
<td>16 Feb 2010</td>
<td>DFA</td>
<td>NAP</td>
<td>DFA positive with FDA-cleared test</td>
<td>...</td>
</tr>
<tr>
<td>4. DIAHERIX Laboratories H1N1-09 Influenza Test</td>
<td>9 Oct 2009</td>
<td>PCR</td>
<td>ABI 9700</td>
<td>NPS, NS, TS, NA, NPA</td>
<td>swH1FluA HA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bead detection</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Qiagen Luminex</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>LiquiChip 100</td>
<td></td>
<td>swH1FluA NAG</td>
</tr>
<tr>
<td>5. DxNA GeneSTAT 2009 A/H1N1Influenza Test</td>
<td>9 Dec 2009</td>
<td>Real-time RT-PCR</td>
<td>GeneSTAT System</td>
<td>NPS, NS</td>
<td>FluA M, swH1FluA HA</td>
</tr>
<tr>
<td>6. ELItech Molecular Diagnostics 2009-H1N1 Influenza A virus Real-Time RT-PCR Test</td>
<td>1 Feb 2010</td>
<td>Real-time RT-PCR</td>
<td>ABI 7900HT</td>
<td>NPS, NS, TS, NA, NW, NPS/TS, BAL, BA, BW, EA, EW, TA, lung tissue</td>
<td>FluA M</td>
</tr>
<tr>
<td>9. Intelligent MDx IMDx 2009 Influenza A H1N1 Real-Time RT-PCR Assay</td>
<td>22 Mar 2010</td>
<td>Real-time RT-PCR</td>
<td>ABI 7500</td>
<td>NPS, NS, TS, NA, NW, NPS/TS, BAL, BA, BW, EA, EW, TA, lung tissue</td>
<td>swH1FluA HA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ABI 7500 Fast Dx</td>
<td>NPS/TS</td>
<td>swH1FluA HA</td>
</tr>
<tr>
<td>10. Longhorn Influenza A/H1N1-09 Prime RT-PCR Assay</td>
<td>16 Feb 2010</td>
<td>Real-time RT-PCR</td>
<td>ABI 7500</td>
<td>NW</td>
<td>FluA M, swH1FluA HA</td>
</tr>
<tr>
<td>11. Prodesse ProFlu-ST Influenza A Assay for the Diagnosis of 2009 H1N1 Influenza Infection</td>
<td>27 Oct 2009</td>
<td>Real-time RT-PCR</td>
<td>Cepheid SmartCycler II</td>
<td>NPS</td>
<td>sh1FluA HA, sh3FluA HA, swH1FluA NP</td>
</tr>
<tr>
<td>12. Qiagen artus Influenza A H1N1 2009 LC RT-PCR Kit</td>
<td>11 Mar 2010</td>
<td>RT-PCR</td>
<td>Roche LightCycler 2.0</td>
<td>NPS</td>
<td>FluA M, swH1FluA HA</td>
</tr>
<tr>
<td>13. Roche RealTime Ready Influenza A/H1N1 Test</td>
<td>13 Nov 2009</td>
<td>Real-time RT-PCR</td>
<td>Roche LightCycler 2.0</td>
<td>NS, NPS, NW, NA</td>
<td>FluA M2, swH1FluA HA</td>
</tr>
</tbody>
</table>
a “public health emergency that affects, or has a significant potential to affect national security, which involved a specified biologic agent or a specified disease or condition that may be attributable to such an agent or agents.” On the basis of this determination, the Secretary of the DHHS declared an emergency justifying EUA of IVD devices designed to detect the 2009 influenza A H1N1 virus. In response, in May 2009 the CDC received an EUA for a molecular-based IVD device that detected the 2009 influenza A H1N1 virus. As of manuscript preparation date, March 2010, EUA has been granted for several modifications to the initial CDC test, 13 additional molecular-based tests, and a DFA reagent from Diagnostic Hybrids. The EUA information can be found at the FDA website (http://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm). The specifics of each test are listed in Table 2 (tests authorized as of 22 March 2010). The majority of the tests use real-time RT-PCR (n = 12), and 2 are performed on closed systems, 1 uses the GeneXpert Dx (Cepheid) (no. 2, Table 2), and 1 uses the GeneSTAT System (DxNA) (no. 5, Table 2). The Simplexa Influenza A (H1N1) 2009 Test (no. 8, Table 2) (Focus Diagnostics) uses a new rapid real-time cycler, the 3M Integrated Cycler (3M Medical Diagnostics). The 3M cycler has a small footprint, about 30.5 cm per side, and a weight of approximately 7 kg. The cycler can process up to 96 samples per run and provides results in 30–75 min. The DIATHERIX Laboratory H1N1-09 Influenza Test uses the Qiagen Luminex LiquiChip 100 (Qiagen) (no. 4, Table 2). The TessArray Resequencing Influenza A Microarray Detection Panel (TessArray) uses the Affymetrix GeneChip Microarray Detection System (Affymetrix) (no. 14, Table 2). Currently, there are little or no published data on the performance of these tests beyond what has been reported in the package inserts.

The EUAs for all tests listed in Table 2 were rescinded as of 23 June 2010. As of July 2010, only 2 of these tests have received FDA approval for use as an IVD device for the diagnosis of 2009 pandemic influenza A H1N1. The first test approved was a new optimized CDC H1N1 assay that is available in CDC-qualified laboratories. The second test is the Focus Diagnostics Simplexa Influenza A H1N1 (2009), which is performed using the 3M Integrated Cycler (3M).

**BENEFITS OF FDA-APPROVED/CLEARED TESTS**

The use of FDA-approved/cleared NAATs, in contrast to laboratory-developed tests, has substantial benefits for the laboratory. Approved tests have undergone extensive analytical and clinical validations during the course of the FDA evaluations. Therefore, performance parameters are well characterized, and the FDA monitors postapproval performance. Most laboratories do not have the expertise and resources to perform extensive
in-house validation studies for laboratory-developed tests as recommended by the Clinical and Laboratory Standards Institute and/or required by CLIA-88, state regulatory agencies, and the College of American Pathologists [reviewed in 42]. The cost to perform a comprehensive laboratory validation of a laboratory-developed test is highly variable and depends on numerous factors, such as the type of assay, (eg, qualitative or quantitative), number of analytes included in the test (eg, singleplex or multiplex), type(s) and number of clinical sample(s), indications for testing (eg, diagnosis, prognosis, or monitoring), technical time to perform studies, and federal and state regulatory requirements. In our laboratory, the development and validation of a laboratory-developed test has cost on average between $20,000 and $50,000 per analyte. FDA-approved/cleared NAATs only require laboratory verification of some of the performance characteristics and a smaller clinical sample correlation study, compared with laboratory-developed tests (Table 3), thereby saving the laboratory considerable cost and technical time. The regulatory requirements for ongoing quality assurance monitoring are also fewer for FDA-approved/cleared NAATs than for laboratory-developed tests [42]. In addition, for regulatory reasons, some health care institutions will only allow the use of FDA-approved/cleared NAATs.

Because the clinical relevance of the assays has been established, the use of FDA-approved/cleared NAATs has a higher chance of reimbursement from both federal and private insurance payors. However, FDA approval/clearance does not guarantee that these tests will be reimbursed, and, if reimbursed, the actual amount of the reimbursement can vary from state to state and by payor. Finally, the simple-to-use fully automated molecular platforms, such as the GeneXpert and GeneSTAT, which incorporate all steps of the test process in a single test cartridge and have random-access sample-in result-out reporting, enable laboratories of all sizes to perform rapid, accurate, and sensitive molecular diagnostic testing.

**LIMITATIONS OF THE CURRENT FDA-APPROVED/CLEARED TESTS**

The most important limitation of the current FDA-approved/cleared NAATs is the lack of tests for the detection of nonviral targets. In particular, NAATs are needed for the detection of atypical pneumonia pathogens. However, the costs of clinical trials for IVD device clearance can sometimes be quite prohibitive (> $10 million, not including the costs of developing and manufacturing the IVD device) and depend on the complexity and clinical relevance of the test and what is required for FDA approval (eg, number of trial sites, number of patients enrolled, clinical indications sought, need for long-term patient follow-up, associated diagnostic procedures [such as biopsy], device evaluations, predicate device comparisons, legal and regulatory components, and so forth). Manufacturers must...
consider the potential number of tests that will be purchased and
the difficulty of the trials for low-prevalence pathogens before
committing the finances and resources to bring such tests
through the approval process. These factors will continue to
limit the scope of FDA-approved/cleared NAATs until the ap-
proval process can be modified to encourage the submission of
NAATs for low-prevalence targets.

The current formats of the NAATs require laboratories to
choose between real-time, easier to perform, more rapid assays
that have limited targets (generally up to 3) and more highly
multiplex tests (>10) that require more hands-on time and
technical steps and more time to result reporting. NAATs with
limited targets would require laboratories to run multiple tests if
a broader range of target detection is indicated. Multiple tests
would increase both the required technical time and the cost per
patient diagnosis. Conversely, the use of multiple, lower multi-
plex tests allows for the selection of the most appropriate pan-
as as related to age of the patient, clinical status, underlying disease,
state of immune competence, and the suspected virus(es). Curr-
ently in development are modified faster versions of the
highly multiplex assays that have been designed to reduce
technical hands-on time and the time to results.

Some of the FDA-approved/cleared real-time NAATs do not
allow the user to see and evaluate the actual amplification
curves. The inability to see the curves makes it difficult to
troubleshoot when problems occur. Although the user should
not be able to alter cutoff values established during the FDA
trials, access to all or part of the raw data is desirable.

One caveat for most qualitative NAATs is that they cannot
distinguish between live and dead organisms and therefore,
depending on the time for nucleic acid clearance, can be limited
in monitoring response to therapy. In addition, with multiple
viral infections, determining the relevance of each virus present
in the sample is difficult, because residual virus detected may
have been from a previous infection and may not be contrib-
uting to the current illness. The development of quantitative
assays and evidence of declining viral load may clarify or resolve
both of these issues.

Finally, issues relating to billing and reimbursement are
substantial. The lack of specific Current Procedural Terminol-
ogy (CPT) codes for each of the individual targets requires
laboratories to bill for multiple targets using the same generic
amplified probe CPT code (87798). Although it is appropriate to
bill for each target present in a multiplex assay, the use of the
same CPT code multiple times for a single test can be prob-
lematic. For example, many laboratory or hospital billing sys-
tems do not recognize multiple similar CPTs for a single test and
will only drop 1 CPT code charge. Some insurance payors will
cover only the charge of the first CPT code, and there are also
limitations on how many times per day a similar CPT code can
be billed. As a result, reimbursement for a highly multiplexed
assay could be limited to 1 charge, thereby significantly in-
creasing the costs to the laboratory and decreasing test prof-
itability. Under these circumstances and with pressure to reduce
medical costs, many administrators will not approve the im-
plementation of this testing if reimbursement is questionable.
Laboratories need analyte-specific CPT codes, and payors
should reimburse for medically relevant NAATs.

**LOOKING TOWARD THE FUTURE**

The North Shore–Long Island Jewish Health System (NS-LIJHS)
Infectious Diseases Molecular Diagnostics Laboratory opened 12
years ago. We performed 3 tests: human immunodeficiency
virus type 1 viral load, AMTD, and *Chlamydia trachomatis/
Neisseria gonorrhoeae* NAATs, with a total testing volume of
5000 tests per year. Today, the laboratory performs NAATs for
40 different pathogens (including bacterial, mycobacterial,
ungal, parasitic, and viral targets), with a volume of more than
225,000 tests per year, and in space that has tripled in size.
Molecular diagnostics for infectious diseases, along with mo-
lar pathology, are 2 of the fastest growing laboratory de-
partments in the NS-LIJHS. In addition, as best exemplified by the
2001 anthrax terrorism event and the 2009 influenza A
H1N1 pandemic, laboratories must be able to respond immedi-
ately by rapidly expanding testing capabilities, including sensitive
and specific molecular diagnostics [43]. At the onset of the
Queens, New York, area 2009 influenza A H1N1 outbreak, the
NS-LIJHS laboratories’ respiratory virus testing volume in-
creased from a baseline of 225 tests per day to more than 950 tests
per day, within 3 days. It was clear from the first week of the
outbreak that the laboratory urgently needed to switch all
influenza testing to molecular methods to obtain sufficient
diagnostic sensitivity and to subtype the influenza strains.
Fortunately, an FDA-approved test, the Luminex xTAG RVP test,
was available and met our diagnostic requirements [5, 24, 43].

Laboratories must continue to plan for future pandemic
outbreaks and bioterror events. Therefore, laboratories are
constantly under pressure to expand testing and meet the de-
mands of their clinical staff and their diverse patient pop-
ulations. To do this, laboratories must provide clinically
relevant, high-quality, cost-effective NAATS that are preferably
FDA approved/cleared. As we move forward, we request that the
FDA work closely with such organizations as the Infectious
Diseases Society of America and the American Society for Mi-
obiology, with laboratory directors, and with IVD device
manufacturers so that this goal can be met. The labor-intensive,
complex methods and platforms of yesterday have evolved into
simpler, user friendly versions that can be applicable to all health
care settings. We encourage the FDA to allow the submission
process to evolve in a similar manner. No longer are the old
“gold standards” of culture applicable, and new ways to evaluate
these tests must be considered [44] so that accurate performance characteristics can be determined in a cost-effective manner. The latter is especially true for low-volume but highly relevant assays, such as quantitative NAATs for transplantation monitoring. In a reasonable and clear regulatory environment, the IVD device manufacturers will succeed in bringing their NAATs through the approval process.

Acknowledgments

I sincerely thank the FDA and the Infectious Diseases Society of America for providing a forum for discussion and exchange of ideas relating to this timely and clinically relevant topic.

Financial support. This work was supported by US Department of Defense Award W81XWH-08-1-0477.

Supplement sponsorship. This article was published as part of a supplement entitled “Workshop on Molecular Diagnostics for Respiratory Tract Infections.” The Food and Drug Administration and the Infectious Diseases Society of America sponsored the workshop. AstraZeneca Pharmaceuticals, Bio Merieux, Inc., Cepheid, Gilead Sciences, Intelligent MDX, Inc., Inverness Medical Innovations, and Roche Molecular Systems provided financial support solely for the purpose of publishing the supplement.

Potential conflicts of interest. C. C. G. is a member of the Scientific Advisory Boards of Gen-Probe/Prodesse and Luminex Molecular Diagnostics. C. C. G. has received research grants and honoraria from Gen-Probe/Prodesse, Luminex Molecular Diagnostics, and Diagnostic Hybrids and research grants from 3M Molecular Diagnostics and has been a consultant for Nanosphere.

References


S324 • CID 2011:52 (Suppl 4) • Ginocchio

Downloaded from https://academic.oup.com/cid/article-abstract/52/suppl_4/S312/422961 by guest on 12 March 2019
[101]. xTAG Respiratory Virus Panel [package insert]. Austin, TX, and Toronto, ON, Canada: Luminex Molecular Diagnostics; 2010.